The US Food and Drug Administration approvals of Vertex Pharmaceuticals Incorporated/CCRISPR Therapeutics AG’s gene editing medicine Casgevy (exagamglogene-autotemcel, exa-cel) and bluebird bio inc.’s gene therapy Lyfgenia (lovotibeglogene autotemcel, lovo-cel) gave doctors two new options to consider for patients with sickle cell disease (SCD) and a lot to discuss about how these novel treatments will be used going forward during the recent American Society of Hematology (ASH) annual meeting.
Key Takeaways
-
Vertex/CRISPR’s Casgevy and bluebird’s Lyfgenia are the first two genetic medicines to treat sickle cell disease, giving doctors and patients a new potentially curative option, but at high costs and with complex administration that may limit the treatments’ use, both within and outside the US.
-
Doctors are trying to determine where the gene editing medicine Casgevy and gene therapy Lyfgenia will fit in the treatment landscape where oral drugs and transplants also are options
The 8 December approvals for both products to treat SCD patients aged 12 and older with recurrent vaso-occlusive crises (VOCs) or a history of vaso-occlusive events (VOEs) were hailed as breakthroughs for the field. However, the complex administration of the one-time therapies and their high list prices – $2.2m for Casgevy and $3
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?